Rejected at 8:28 p.m. Oct, 31, 2023 ] by dollajas
Author: dopamine
Related Note: 1495740310438
Rationale for change

Contents of the card are completely irrelevant to the tagged B&B video

Rejection reason

resolved manually

Text
Cyclophosphamide can be used as an immunosuppressant for the treatment of {{c1::lupus}} nephritis, as well as for systemic {{c2::vasculitides}}
Extra
e.g. eosinophilic granulomatosis with polyangiitis (EGPA), microscopic polyangiitis, Henoch-Schönlein purpura, granulomatosis with polyangiitis (GPA), polyarteritis nodosa

- When given for vasculitides, often given with corticosteroids
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize

Physeo

OME

Additional Resources
Empty field
One by one
Empty field
Changed Tags
#AK_Step1_v12::#B&B::08_Endocrinology::04_Repro::01_Repro_Hormones #AK_Step1_v12::#OME_banner::Clinical::07_Endocrinology
#AK_Step1_v12::^Other::^EXPN #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::11_Busulfan_Cyclophosphamide_Ifosfamide_Nitorsureas #AK_Step1_v12::#Physeo::^physeo_image_update !AK_UpdateTags::Step1decks::Zanki-Pharmacology #AK_Step1_v12::#Pixorize::01_Biochemistry::13_Vasculitides::06_Granulomatosis_with_Polyangiitis #AK_Step1_v12::#Pixorize::01_Biochemistry::13_Vasculitides::08_Microscopic_Polyangiitis #AK_Step1_v12::#FirstAid::10_Hematology_Oncology::05_Pharm::13_Alkylating_Agents::Cyclophosphamide #AK_Step1_v12::#B&B::11_Hematology::04_Cancer_Drugs::02_Alkylating_Agents #AK_Step1_v12::^Other::^HighYield::2-RelativelyHighYield #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::02_DNA_&_Cellular_Division::01_Alkylating_Agents::zanki_extra #AK_Step1_v12::#FirstAid::10_Hematology_Oncology::05_Pharm::13_Alkylating_Agents #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::08_Cyclophosphamide/Ifosfamide